Virbac's Technical Services Manager, Matt Wells, highlights the evolving epidemiology of leptospirosis in New Zealand, the associated heightened public health risk, and the role of newly developed Lepto 4-Way in managing this.
We respect your privacy
You are about to leave the Virbac New Zealand website.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you are about to enter may not be suitable for use in your country.